1. [Dynamics of cognitive impairments during L-dopa therapy in Parkinson's disease].
- Author
-
Ismailova SB, Prokopenko SV, Pokhabov DV, Mosaleva EI, Alekseenko PV, and Zhumzhanov IM
- Subjects
- Aged, Antiparkinson Agents adverse effects, Cognition, Humans, Levodopa adverse effects, Mental Status and Dementia Tests, Cognitive Dysfunction chemically induced, Cognitive Dysfunction drug therapy, Parkinson Disease drug therapy
- Abstract
Objective: To assess the dynamics of cognitive impairments (CI) in patients with Parkinson's disease (PD) during L-dopa therapy., Material and Methods: The randomized clinical study included 41 patients with a refined diagnosis of PD 2.5-3.5 stages by Hoehn-Yahr scale, mainly with akinetic-rigid and mixed forms, and with CI associated with PD. All patients were on levodopa therapy. The average duration of the disease was 5 years. The study participants were randomized into two groups according to the design. To assess the dynamics of CI, a neuropsychological study was carried out twice with an interval of 6 months: in group I - at the «peak and outcome» of L-DOPA therapy, and in group II - at the «outcome and peak» of levodopa therapy, respectively. Assessment of cognitive functions (CF) was carried out using Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Frontal Assessment Battery (FAB), Scales for Outcomes in Parkinson's Disease-Cognition (SCOPA-Cog), Geriatric Depression Scale (GDS)., Results: The statistically significant improvement of CF at the «peak» of levodopa drugs and the deterioration at the «outcome» of L-DOPA therapy in the form of an increase in CI ( p <0.05) was revealed., Conclusion: CI in PD, in a certain extent, may be dependent on L-DOPA therapy as well as motor manifestations. The most dependent on L-DOPA therapy CF were attention, speech, executive and visual-spatial functions.
- Published
- 2021
- Full Text
- View/download PDF